NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. (“Design” or the “Company”) DSGN. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether Design and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On or about March 24, 2021, Design completed its initial public offering (“IPO”), selling 12 million shares at a price of $20.00 per share. Then, on December 7, 2022, Design released initial data from a Phase 1 study of DT-216 in patients with Friedreich’s Ataxia. Among other findings, Design said that 16 patients on DT-216 and eight on placebo reported at least one treatment-emergent adverse event. As a result of this news, Design’s share price fell sharply during intraday trading on December 8, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980